Search


Naevus or melanoma? Lessons from an ocular oncologist

Professor Heinrich Heimann spoke to delegates about signs of cancer in the eye during the Hospital and Specialty Optometrists Conference

Professor Heinrich Heimann speaks at the Hospital and Specialty Optometrists Conference
OT

Royal Liverpool and Broadgreen University Hospital NHS Trust consultant ophthalmic surgeon, Professor Heinrich Heimann, delivered a presentation on ocular oncology at the Hospital and Specialty Optometrists Conference (14–15 November, London).

Heimann told delegates that over the past decade referrals from optometry practices to ocular oncology have increased significantly with advances in imaging technology.

“My colleague and I now spend about four or five hours a week sifting through referrals to see who needs to come to us,” he said.

“The incidence hasn’t changed – it’s the same number of melanomas – but so many more lesions are picked up with modern imaging,” Heimann shared.

The ocular oncologist highlighted that assessing a potential uveal melanoma can be a difficult balance.

“On the one hand, you don’t want to miss a tumour, but on the other hand, you don’t want to over diagnose,” he said.

Heimann emphasised to delegates the importance of proper documentation when assessing a possible case of uveal melanoma.

He added that prior images of a lesion help him to determine if it has grown in size.

“If it’s growing, it might be a melanoma. If it’s the same for 20 years, it’s probably naevus,” Heimann said.

“Please share images if you have them. The older the better. Even if it is out of focus or only part of the lesion,” he shared.

Reflecting on the cases he sees within ocular oncology, Heimann observed that 30% of patients have no symptoms.

“What people don’t understand is that there is no typical cancer symptom,” he said.

“In particular, everybody thinks cancer causes pain. No – it doesn’t. Only 2% of our patients have pain as an initial symptom,” Heimann said.

He noted that there are pain fibres at the front of the eye and in the ciiliary body, but not at the back of the eye where tumours are commonly located.

Heimann noted that there is a higher rate of uveal melanoma among white populations, than Asian or black populations – although people from these backgrounds can still develop this form of cancer.

“Generally, the less pigmented you are, the higher the incidence,” he said.

Heimann shared that a Danish study found around 2.5% of people had a choroidal naevus.

The consultant ophthalmic surgeon outlined the two systems that people use when assessing lesions – known by the acronyms TFSOM–DIM and MOLES.

He noted that MOLES is the latest approach to assessing lesions in the UK. The mnemonic stands for Mushroom shape, Orange pigment, Large size, Enlarging tumour and Subretinal fluid.

“This is your toolkit to look at these lesions and to refer them to the either the hospital or to the oncology unit,” Heimann highlighted.

He highlighted that orange pigment and subretinal fluid are the most important clinical signs to look out for when differentiating a melanoma from a naevus.

“What’s typical for orange pigment? If you use autofluorescence, it shows you these patches and these plaques, like cow or giraffe patches or leopard spots,” Heimann said.

The ocular oncologist noted that naevus can grow in young patients without becoming a melanoma.

“We know not everything that grows is a melanoma, but it depends on the age group. If a naevus is growing in a 75-year-old, I would think this is very likely a melanoma,” Heimann observed.

The ophthalmic surgeon briefly discussed an emerging treatment option for uveal melanoma – darovasertib. Heimann shared that the early results with this medication are promising in terms of shrinking tumours and preventing enucleation.

He added that there are also signs the medication can prevent metastatic disease.

Heimann is a consultant for the company that is producing the drug, which is currently in Phase III trials.

“I’m sure in the very near future patients will be treated with a drug first before they get radiotherapy,” he said.

Heimann shared his guidance for practitioners on what they should be aware of when caring for patients who have received treatment for uveal melanoma.

He noted that radiotherapy often results in ocular surface issues, while pigmentation can occasionally develop following treatment.

Heimann observed that patients will often be worried about tumour reoccurrence.

“One of the common misconceptions is that pain is a sign of reoccurrence,” he said.

The ocular oncologist shared that this is unlikely to be the case as the tumour site in uveal melanoma is rarely located close to pain fibres.

He shared that patients will also present worried that headaches are a sign the cancer has spread to the brain, but this is rare in uveal melanoma.